Hong Kong—Changmao Biochemical Engineering Company Limited (CHANGMAO BIO) filed its monthly return for the period ended 30 June 2026, confirming a stable capital base and full compliance with Hong Kong Stock Exchange (HKEX) public-float requirements.
Key highlights:
1. Authorised and Registered Capital • Ordinary H shares: 183.70 million shares at RMB 0.10 par value, representing RMB 18.37 million of authorised capital—unchanged from May 2026. • Domestic shares: 2.50 million shares at RMB 0.10, equal to RMB 0.25 million—unchanged. • Foreign shares: 343.50 million shares at RMB 0.10, equal to RMB 34.35 million—unchanged. Total authorised capital across all classes remained RMB 52.97 million.
2. Issued Share Capital and Treasury Position • Listed H shares in issue: 183.70 million; no treasury shares were held or cancelled during the month. • Unlisted domestic shares: 2.50 million, unchanged. • Unlisted foreign shares: 343.50 million, unchanged. No movements occurred in any class—no new issuance, repurchase, or cancellations.
3. Public Float Compliance The company confirmed that at 30 June 2026 it satisfied the HKEX minimum public-float threshold of 25% for its H shares.
4. Capital Instruments and Corporate Actions • No share option grants, exercises, lapses, or cancellations. • No warrants, convertibles, or other equity-linked instruments outstanding or exercised. • No other share issuance agreements, redemptions, or treasury-share transactions were reported.
The filing, signed by Company Secretary Ms. Wan Pui Ling Alice, affirms adherence to all applicable listing rules and regulatory requirements during the reporting month.